Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 4 days ago

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcoleps... Full story

Yahoo Finance • 5 days ago

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchi... Full story

Yahoo Finance • 9 days ago

Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More

Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in u... Full story

Yahoo Finance • 10 days ago

Takeda Wins FDA Nod For ORZEYFUL, First Orexin Therapy For Narcolepsy Type 1

(RTTNews) - Takeda (TAK) announced that the U.S. FDA has approved ORZEYFUL, an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1) in adults. Narcolepsy type 1 is a rare, chronic neurological disorder cause... Full story

Yahoo Finance • 11 days ago

AC Immune First Half 2026 Financial and Corporate Update

AC Immune SA AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with... Full story

Yahoo Finance • 17 days ago

Takeda Pharmaceutical Q1 Earnings Call Highlights

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely of... Full story

Yahoo Finance • 17 days ago

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (ovepor... Full story

Yahoo Finance • 23 days ago

Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

Asian equities traded in the US as American depositary receipts were tracking lower Friday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 30 days ago

Preclinical Stage Partnering Deals in Pharmaceuticals and Biotechnology 2020-2026: Analyze Over 1,750 Partnering Agreements

Dublin, July 17, 2026 (GLOBE NEWSWIRE) -- The "Preclinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensiv... Full story

Yahoo Finance • last month

Nvidia CEO Huang visits Japan, unveils AI partnerships across key industries

[Moscow, Russia - April 7, 2019: NVIDIA video chip on the motherboard] Antonio Bordunovi/iStock Editorial via Getty Images Nvidia (NVDA [https://seekingalpha.com/symbol/NVDA]) on Wednesday unveiled a broad slate of AI products, partnershi... Full story

Yahoo Finance • last month

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, invest... Full story

Yahoo Finance • last month

Takeda Pharmaceutical to invest $30M in Indonesia's new national plasma donation network

[Takeda California Inc in San Diego, CA, USA.] JHVEPhoto/iStock Editorial via Getty Images Takeda Pharmaceutical (TAK [https://seekingalpha.com/symbol/TAK]) and the Indonesian Government have launched a landmark collaboration [https://see... Full story

Yahoo Finance • last month

Takeda And Indonesia Announce Plasma Collaboration To Build ASEAN's First Regional Hub

(RTTNews) - Takeda (TAK) and the Government of Indonesia announced a collaboration to strengthen Indonesia's plasma ecosystem. This initiative aims to expand equitable access to lifesaving plasma-derived medicinal products (PDMPs) both wit... Full story

Yahoo Finance • 2 months ago

Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best low-priced pharma stocks on this list. TheFly reported on June 23 that TAK announced... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candi... Full story

Yahoo Finance • 2 months ago

Takeda finalizes 18-month transition: Julie Kim officially appointed President & CEO

Takeda (TAK [https://seekingalpha.com/symbol/TAK]) has completed its 18-month leadership transition. Following a shareholder vote at the company’s 150th annual general meeting of shareholders, the board of directors formally appointed [htt... Full story

Yahoo Finance • 2 months ago

AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus

BCC Research LLC "The Pulse Report highlights AI's growing role in preclinical and translational development as biopharma companies seek competitive advantage in bispecific antibodies." Boston, June 15, 2026 (GLOBE NEWSWIRE) -- Artificia... Full story

Yahoo Finance • 2 months ago

Takeda gets FDA review for Entyvio label expansion in children

[Takeda Pharmaceutical Company. Takeda recently acquired Irish drugmaker Shire I] jetcityimage/iStock Editorial via Getty Images * Takeda (TAK [https://seekingalpha.com/symbol/TAK]) announced that the Food and Drug Administration has ac... Full story

Yahoo Finance • 2 months ago

FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease; PDUFA Set In Q1,2027

(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application or sBLA for intravenous ENTYVIO (vedolizumab) for the treatment of... Full story

Yahoo Finance • 3 months ago

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement to keep market monopoly of its constipation drug Amitiza (lubipr... Full story